Zimmer Biomet beats Q1 estimates, raises guidance By Investing.com

Zimmer Biomet beat Q1 expectations with adjusted EPS of $2.09 versus $1.87 consensus and revenue of $2.09 billion versus $2.06 billion, with sales up 9.3% year over year. The company raised full-year adjusted EPS guidance to $8.40-$8.55, while maintaining full-year revenue growth guidance of 2.5%-4.5%. Shares rose 0.4% after the release, and the S.E.T. segment led growth at 19.5%.

Analysis

The key read-through is not just that execution improved, but that Zimmer Biomet is getting leverage from a product-cycle inflection while still showing enough discipline to translate growth into cash. In medtech, that combination matters because the market usually pays up only when revenue acceleration is seen as repeatable rather than episodic; the raised EPS guide implies the company is not buying growth with margin erosion. The 19.5% growth in the highest-momentum segment suggests the mix is shifting toward categories where launch success can compound for multiple quarters, which is more important than a single beat.

Second-order, this is mildly negative for slower-moving orthopedics peers that are still leaning on pricing rather than volume and innovation. If ZBH is sustaining above-market growth in a core elective-care category, it raises the bar for incumbents with weaker launch cadence and creates a competitive wedge with hospitals and ambulatory surgery centers that prefer vendors with broader product breadth and reliable fill rates. It also hints at better utilization across the supply chain, which can support component suppliers and contract manufacturers, but the bigger implication is share capture from more exposed rivals.

The market may be underestimating how much of the EPS upside is coming from operating leverage rather than one-time cost control. That makes the next catalyst window 1-2 quarters, not just the next earnings print: if revenue stays mid-to-high single digit and guidance is still conservative, the stock can re-rate on durability. The main reversal risk is that procedure demand normalizes faster than expected or that international growth proves less sticky once launch-related demand lapses; in that case, the multiple expansion thesis would fade before the fundamental story fully breaks.

Key Decisions for Investors

• Long ZBH for 3-6 months on continued product-cycle momentum; target a re-rating if management proves the raised EPS guide is driven by mix and leverage rather than transitory cost cuts. Risk: a sharp slowdown in elective procedure volumes would compress the thesis quickly.
• Pair trade: long ZBH / short a slower-growth orthopedics peer with weaker launch cadence over the next 1-2 quarters. The trade works if the market keeps rewarding above-consensus organic growth and penalizing share-losers in the same end market.
• Buy ZBH call spreads into the next earnings cycle to express upside from another guidance raise while capping premium outlay. Best setup is 2-4 weeks after any post-earnings drift if implied volatility falls but fundamentals remain intact.
• Use any pullback below the post-earnings level to add, rather than chase strength immediately. The stock is more likely to work on a staggered re-rating than a straight line move, given the market’s tendency to wait for confirmation on durable end-market demand.